ABCL
Price
$2.97
Change
+$0.03 (+1.02%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
877.24M
38 days until earnings call
DNA
Price
$10.83
Change
+$0.63 (+6.18%)
Updated
Jan 17 closing price
Capitalization
622.5M
Ad is loading...

ABCL vs DNA

Header iconABCL vs DNA Comparison
Open Charts ABCL vs DNABanner chart's image
AbCellera Biologics
Price$2.97
Change+$0.03 (+1.02%)
Volume$18.96K
Capitalization877.24M
Ginkgo Bioworks Holdings
Price$10.83
Change+$0.63 (+6.18%)
Volume$1.19M
Capitalization622.5M
ABCL vs DNA Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABCL vs. DNA commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and DNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (ABCL: $2.97 vs. DNA: $10.83)
Brand notoriety: ABCL and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 56% vs. DNA: 81%
Market capitalization -- ABCL: $877.24M vs. DNA: $622.5M
ABCL [@Biotechnology] is valued at $877.24M. DNA’s [@Biotechnology] market capitalization is $622.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, DNA is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 4 TA indicator(s) are bullish while DNA’s TA Score has 3 bullish TA indicator(s).

  • ABCL’s TA Score: 4 bullish, 3 bearish.
  • DNA’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than DNA.

Price Growth

ABCL (@Biotechnology) experienced а +1.71% price change this week, while DNA (@Biotechnology) price change was +10.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

ABCL is expected to report earnings on May 13, 2025.

DNA is expected to report earnings on Nov 11, 2024.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($877M) has a higher market cap than DNA($622M). DNA YTD gains are higher at: 10.285 vs. ABCL (1.365). ABCL has higher annual earnings (EBITDA): -202.4M vs. DNA (-630.64M). ABCL (643M) and DNA (616M) have equal amount of cash in the bank . ABCL has less debt than DNA: ABCL (71.4M) vs DNA (446M). DNA has higher revenues than ABCL: DNA (217M) vs ABCL (33M).
ABCLDNAABCL / DNA
Capitalization877M622M141%
EBITDA-202.4M-630.64M32%
Gain YTD1.36510.28513%
P/E RatioN/AN/A-
Revenue33M217M15%
Total Cash643M616M104%
Total Debt71.4M446M16%
TECHNICAL ANALYSIS
Technical Analysis
ABCLDNA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
86%
Momentum
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 11 days ago
80%
MACD
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 11 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 11 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
73%
Bullish Trend 11 days ago
76%
Advances
ODDS (%)
Bullish Trend 13 days ago
77%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCPIX32.520.17
+0.53%
Fidelity Advisor Intl Cap App I
TIMVX18.410.09
+0.49%
Nuveen Mid Cap Value R6
IMEGX19.410.09
+0.47%
Macquarie Systematic Em Mkts Eq R6
VIOAX9.710.02
+0.21%
VELA Income Opportunities A
PIIDX12.66N/A
N/A
Principal International Equity R-6

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with VCYT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+1.02%
VCYT - ABCL
56%
Loosely correlated
-1.27%
PRME - ABCL
54%
Loosely correlated
+0.70%
BEAM - ABCL
53%
Loosely correlated
+0.17%
AURA - ABCL
53%
Loosely correlated
+1.30%
DNA - ABCL
52%
Loosely correlated
+6.18%
More